The Journal of Immunology, Vol 142, Issue 3 971-978, Copyright © 1989 by American Association of Immunologists

ARTICLES

Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46

TJ Palker, ME Tanner, RM Scearce, RD Streilein, ME Clark and BF Haynes
Department of Medicine, Duke University Medical Center, Durham, NC 27710.

Antigenic sites on human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins that are immunogenic in man were studied with envelope gene (env)-encoded synthetic peptides and a mAb to HTLV-I gp46 envelope glycoprotein. Antibodies in 78% of sera from HTLV-I seropositive subjects reacted with synthetic peptide 4A (amino acids 190 to 209) from a central region of HTLV-I gp46. Human anti-HTLV-I antibodies also bound to synthetic peptides 6 (29% of sera) and 7 (18% of sera) from a C-terminal region of gp46 (amino acids 296 to 312) and an N-terminal region of gp21 (amino acids 374 to 392), respectively. mAb 1C11 raised to affinity-purified HTLV-I gp46 reacted with gp46 external envelope glycoprotein and gp63 envelope precursor in immunoblot assay and also bound to the surface of HTLV-I+ cells lines HUT-102 and MT-2. Antibody 1C11 did not react with HTLV-II or HIV- infected cells or with a broad panel of normal human tissues or cell lines. In competitive RIA, anti-gp46 antibody 1C11 was inhibited from binding to gp46 either by antibodies from HTLV-I seropositive subjects or by HTLV-I env-encoded synthetic peptide 4A, indicating that 1C11 bound to or near a site on gp46 within amino acids 190 to 209 also recognized by antibodies from HTLV-I-seropositive individuals. When tested in syncytium inhibition assay, mAb 1C11 did not neutralize the infectivity of HTLV-I. Thus, HTLV-I infection in man is associated with a major antibody response to a region of gp46 within amino acids 190 to 209 that is on the surface of virus-infected cells.

This article has been cited by other articles:

				L. R. Silverman, A. J. Phipps, A. Montgomery, S. Fernandez, T. Tsukahara, L. Ratner, and M. D. Lairmore In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations Blood, November 15, 2005; 106(10): 3602 - 3608. [Abstract] [Full Text] [PDF]

				H. Kobayashi, T. Nagato, M. Yanai, K. Oikawa, K. Sato, S. Kimura, M. Tateno, R. Omiya, and E. Celis Recognition of Adult T-Cell Leukemia/Lymphoma Cells by CD4+ Helper T Lymphocytes Specific for Human T-Cell Leukemia Virus Type I Envelope Protein Clin. Cancer Res., October 15, 2004; 10(20): 7053 - 7062. [Abstract] [Full Text] [PDF]

				R. Sundaram, M. P. Lynch, S. V. Rawale, Y. Sun, M. Kazanji, and P. T. P. Kaumaya De Novo Design of Peptide Immunogens That Mimic the Coiled Coil Region of Human T-cell Leukemia Virus Type-1 Glycoprotein 21 Transmembrane Subunit for Induction of Native Protein Reactive Neutralizing Antibodies J. Biol. Chem., June 4, 2004; 279(23): 24141 - 24151. [Abstract] [Full Text] [PDF]

				T. Tsukahara, M. M. Wielgosz, and L. Ratner Characterization of Envelope Glycoprotein Mutants for Human T-Cell Leukemia Virus Type 1 Infectivity and Immortalization J. Virol., October 1, 2001; 75(19): 9553 - 9559. [Abstract] [Full Text] [PDF]

				W. Ding, B. Albrecht, R. Luo, W. Zhang, J. R. L. Stanley, G. C. Newbound, and M. D. Lairmore Endoplasmic Reticulum and cis-Golgi Localization of Human T-Lymphotropic Virus Type 1 p12I: Association with Calreticulin and Calnexin J. Virol., August 15, 2001; 75(16): 7672 - 7682. [Abstract] [Full Text] [PDF]

				V. Richard, M. D. Lairmore, P. L. Green, G. Feuer, R. S. Erbe, B. Albrecht, C. D'Souza, E. T. Keller, J. Dai, and T. J. Rosol Humoral Hypercalcemia of Malignancy : Severe Combined Immunodeficient/Beige Mouse Model of Adult T-Cell Lymphoma Independent of Human T-Cell Lymphotropic Virus Type-1 Tax Expression Am. J. Pathol., June 1, 2001; 158(6): 2219 - 2228. [Abstract] [Full Text] [PDF]

				B. Albrecht, N. D. Collins, M. T. Burniston, J. W. Nisbet, L. Ratner, P. L. Green, and M. D. Lairmore Human T-Lymphotropic Virus Type 1 Open Reading Frame I p12I Is Required for Efficient Viral Infectivity in Primary Lymphocytes J. Virol., November 1, 2000; 74(21): 9828 - 9835. [Abstract] [Full Text]

				N. D. Collins, C. D'Souza, B. Albrecht, M. D. Robek, L. Ratner, W. Ding, P. L. Green, and M. D. Lairmore Proliferation Response to Interleukin-2 and Jak/Stat Activation of T Cells Immortalized by Human T-Cell Lymphotropic Virus Type 1 Is Independent of Open Reading Frame I Expression J. Virol., November 1, 1999; 73(11): 9642 - 9649. [Abstract] [Full Text] [PDF]

				A. R. Rosenberg, L. Delamarre, C. Pique, I. Le Blanc, G. Griffith, and M.-C. Dokhelar Early Assembly Step of a Retroviral Envelope Glycoprotein: Analysis Using a Dominant Negative Assay J. Cell Biol., April 5, 1999; 145(1): 57 - 68. [Abstract] [Full Text] [PDF]

				K. G. Hadlock, J. Rowe, and S. K. H. Foung The Humoral Immune Response to Human T-Cell Lymphotropic Virus Type 1 Envelope Glycoprotein gp46 Is Directed Primarily against Conformational Epitopes J. Virol., February 1, 1999; 73(2): 1205 - 1212. [Abstract] [Full Text]

				P. Hollsberg and D. A. Hafler Pathogenesis of Diseases Induced by Human Lymphotropic Virus Type I Infection N. Engl. J. Med., April 22, 1993; 328(16): 1173 - 1182. [Full Text]

				F. J. Kim, I. Seiliez, C. Denesvre, D. Lavillette, F.-L. Cosset, and M. Sitbon Definition of an Amino-terminal Domain of the Human T-cell Leukemia Virus Type 1 Envelope Surface Unit That Extends the Fusogenic Range of an Ecotropic Murine Leukemia Virus J. Biol. Chem., July 28, 2000; 275(31): 23417 - 23420. [Abstract] [Full Text] [PDF]